

Dennie T Frederick

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9927800/publications.pdf>

Version: 2024-02-01

84
papers

15,099
citations

61945

43
h-index

64755

79
g-index

87
all docs

87
docs citations

87
times ranked

25493
citing authors

#	ARTICLE	IF	CITATIONS
1	Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma. <i>Cell Reports Medicine</i> , 2022, 3, 100500.	3.3	13
2	Benefit and toxicity of programmed death-1 blockade vary by ethnicity in patients with advanced melanoma: an international multicentre observational study. <i>British Journal of Dermatology</i> , 2022, 187, 401-410.	1.4	21
3	STAG2 regulates interferon signaling in melanoma via enhancer loop reprogramming. <i>Nature Communications</i> , 2022, 13, 1859.	5.8	21
4	Landscape of helper and regulatory antitumour CD4+ T cells in melanoma. <i>Nature</i> , 2022, 605, 532-538.	13.7	70
5	Glycoproteomics as a powerful liquid biopsy-based predictor of checkpoint inhibitor treatment benefit in metastatic malignant melanoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9545-9545.	0.8	4
6	Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition. <i>Cancer Immunology Research</i> , 2022, 10, 996-1012.	1.6	18
7	Abstract 1270: Glycoproteomics-based liquid biopsy informs optimal checkpoint-inhibitor drug choice. <i>Cancer Research</i> , 2022, 82, 1270-1270.	0.4	0
8	Abstract 3610: In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer. <i>Cancer Research</i> , 2022, 82, 3610-3610.	0.4	0
9	HRS phosphorylation drives immunosuppressive exosome secretion and restricts CD8+ T-cell infiltration into tumors. <i>Nature Communications</i> , 2022, 13, .	5.8	23
10	Adjuvant Radiation Therapy for Clinical Stage III Melanoma in the Modern Therapeutic Era. <i>Annals of Surgical Oncology</i> , 2021, 28, 3512-3521.	0.7	8
11	Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	54
12	Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohort. , 2021, 9, e002092.		7
13	The use of cryoablation to overcome resistance to PD-1 blockade in unresectable melanoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9538-9538.	0.8	1
14	Characterizing the tumor and immune landscape of melanoma patients treated with combined checkpoint blockade and MAPK targeted therapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9522-9522.	0.8	1
15	Evolution of delayed resistance to immunotherapy in a melanoma responder. <i>Nature Medicine</i> , 2021, 27, 985-992.	15.2	67
16	Abstract 387: Glycoproteomics as a powerful liquid biopsy-based predictor of checkpoint-inhibitor treatment response. <i>Cancer Research</i> , 2021, 81, 387-387.	0.4	2
17	Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma. <i>Nature</i> , 2021, 596, 119-125.	13.7	239
18	Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-“PD-1 Monotherapy. <i>Clinical Cancer Research</i> , 2021, 27, 5993-6000.	3.2	70

#	ARTICLE	IF	CITATIONS
19	Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance. <i>Cancer Research</i> , 2021, 81, 5230-5241.	0.4	9
20	Absolute quantification of tumor antigens using embedded MHC-I isotopologue calibrants. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	25
21	Pathway signatures derived from on-treatment tumor specimens predict response to anti-PD1 blockade in metastatic melanoma. <i>Nature Communications</i> , 2021, 12, 6023.	5.8	21
22	Fitness Landscape of Clonal Hematopoiesis Under Selective Pressure of Immune Checkpoint Blockade. <i>JCO Precision Oncology</i> , 2020, 4, 1027-1033.	1.5	20
23	Plasma-derived extracellular vesicle analysis and deconvolution enable prediction and tracking of melanoma checkpoint blockade outcome. <i>Science Advances</i> , 2020, 6, .	4.7	37
24	Reversal of pre-existing NGFR-driven tumor and immune therapy resistance. <i>Nature Communications</i> , 2020, 11, 3946.	5.8	71
25	Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma. <i>Clinical Cancer Research</i> , 2020, 26, 6039-6050.	3.2	24
26	Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring. <i>Nature Medicine</i> , 2020, 26, 1114-1124.	15.2	216
27	SPANX Control of Lamin A/C Modulates Nuclear Architecture and Promotes Melanoma Growth. <i>Molecular Cancer Research</i> , 2020, 18, 1560-1573.	1.5	13
28	Changes in Aged Fibroblast Lipid Metabolism Induce Age-Dependent Melanoma Cell Resistance to Targeted Therapy via the Fatty Acid Transporter FATP2. <i>Cancer Discovery</i> , 2020, 10, 1282-1295.	7.7	75
29	Targeting the cyclin-dependent kinase 5 in metastatic melanoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 8001-8012.	3.3	21
30	Heterogeneous response and irAE patterns in advanced melanoma patients treated with anti-PD-1 monotherapy from different ethnic groups: Subtype distribution discrepancy and beyond.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10020-10020.	0.8	2
31	Investigating the tumor immune infiltrate for populations that predict immune-related adverse events (irAEs) in patients receiving PD-1 inhibitors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3116-3116.	0.8	0
32	The use of plasma proteomic markers to understand the biology of immunotherapy response.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10062-10062.	0.8	0
33	Correlation between immune-related adverse events and outcomes in nivolumab/ipilimumab combination therapy for metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 58-58.	0.8	1
34	A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of <i>BRAF</i> -mutated Melanoma to MAPK Inhibitors. <i>Clinical Cancer Research</i> , 2019, 25, 6852-6867.	3.2	74
35	Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway Activation. <i>Clinical Cancer Research</i> , 2019, 25, 7202-7217.	3.2	29
36	Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy. <i>Immunity</i> , 2019, 50, 1498-1512.e5.	6.6	406

#	ARTICLE	IF	CITATIONS
37	Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 897-905.	2.0	38
38	Genome-wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy. <i>Molecular Systems Biology</i> , 2019, 15, e8323.	3.2	25
39	Gut microbiota dependent anti-tumor immunity restricts melanoma growth in Rnf5 mice. <i>Nature Communications</i> , 2019, 10, 1492.	5.8	114
40	ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma. <i>Cancer Discovery</i> , 2019, 9, 396-415.	7.7	71
41	Predictable early onset high-dose-glucocorticoid-associated-irAE and its predictive role in anti-PD-1 monotherapy treated advanced melanoma patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9544-9544.	0.8	2
42	Liquid biopsy using plasma proteomic profiling to reveal predictors of immunotherapy response.. <i>Journal of Clinical Oncology</i> , 2019, 37, 130-130.	0.8	1
43	Organ site-specific radiological responses in anti-PD-1 monotherapy treated advanced melanoma patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9552-9552.	0.8	0
44	Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma. <i>EMBO Molecular Medicine</i> , 2018, 10, .	3.3	79
45	A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma. <i>Oncolmmunology</i> , 2018, 7, e1423172.	2.1	25
46	Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma. <i>Clinical Cancer Research</i> , 2018, 24, 4771-4784.	3.2	29
47	A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. <i>Cell</i> , 2018, 175, 984-997.e24.	13.5	892
48	Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. <i>Cell</i> , 2018, 175, 998-1013.e20.	13.5	1,260
49	Toward Minimal Residual Disease-Directed Therapy in Melanoma. <i>Cell</i> , 2018, 174, 843-855.e19.	13.5	514
50	Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. <i>Nature Medicine</i> , 2018, 24, 1545-1549.	15.2	473
51	Feasibility of Ultra-High-Throughput Functional Screening of Melanoma Biopsies for Discovery of Novel Cancer Drug Combinations. <i>Clinical Cancer Research</i> , 2017, 23, 4680-4692.	3.2	8
52	An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition. <i>Journal of Experimental Medicine</i> , 2017, 214, 1691-1710.	4.2	71
53	Resistance to checkpoint blockade therapy through inactivation of antigen presentation. <i>Nature Communications</i> , 2017, 8, 1136.	5.8	686
54	PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. <i>Nature</i> , 2017, 550, 133-136.	13.7	146

#	ARTICLE	IF	CITATIONS
55	Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. <i>Science</i> , 2017, 357, 1156-1160.	6.0	1,059
56	Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure. <i>EMBO Molecular Medicine</i> , 2017, 9, 1011-1029.	3.3	63
57	Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence. <i>Cell Reports</i> , 2017, 21, 2796-2812.	2.9	77
58	Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines. <i>Cell Reports</i> , 2017, 21, 1936-1952.	2.9	72
59	A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma. <i>Cell Reports</i> , 2017, 21, 1953-1967.	2.9	117
60	sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. <i>Nature</i> , 2016, 532, 250-254.	13.7	290
61	Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. <i>Science</i> , 2016, 352, 189-196.	6.0	3,421
62	Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade. <i>Cancer Immunology Research</i> , 2016, 4, 959-967.	1.6	428
63	Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma. <i>Nature Medicine</i> , 2016, 22, 1056-1061.	15.2	62
64	Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. <i>Nature Communications</i> , 2016, 7, 10582.	5.8	412
65	Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor Resistance. <i>Cancer Discovery</i> , 2016, 6, 382-399.	7.7	139
66	Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy. <i>Cancer Cell</i> , 2016, 29, 270-284.	7.7	198
67	Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. <i>Oncimmunology</i> , 2016, 5, e1136044.	2.1	55
68	Genomic analysis and 3-y efficacy and safety update of COMBI-d: A phase 3 study of dabrafenib (D) + trametinib (T) vs D monotherapy in patients (pts) with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 9502-9502.	0.8	47
69	Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR. <i>Nature Medicine</i> , 2015, 21, 741-750.	15.2	107
70	Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation. <i>Cell Reports</i> , 2015, 11, 1458-1473.	2.9	55
71	The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. <i>Nature Genetics</i> , 2015, 47, 250-256.	9.4	434
72	EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma. <i>Cancer Discovery</i> , 2015, 5, 274-287.	7.7	107

#	ARTICLE	IF	CITATIONS
73	Melanocytic nevi excised during B-Raf proto-oncogene (BRAF) inhibitor therapy: A study of 19 lesions from 10 patients. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 491-499.e2.	0.6	14
74	MITF Modulates Therapeutic Resistance through EGFR Signaling. <i>Journal of Investigative Dermatology</i> , 2015, 135, 1863-1872.	0.3	76
75	BAP1 Has a Survival Role in Cutaneous Melanoma. <i>Journal of Investigative Dermatology</i> , 2015, 135, 1089-1097.	0.3	31
76	A phase II study of combined therapy with vemurafenib (vem) and high-dose interleukin-2 (aldesleukin;) Tj ETQq0 0.0rgBT /Oyerlock 10	0.8	2
77	Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment. <i>PLoS ONE</i> , 2015, 10, e0140310.	1.1	39
78	One Hippo and many masters: differential regulation of the Hippo pathway in cancer. <i>Biochemical Society Transactions</i> , 2014, 42, 816-821.	1.6	12
79	Inhibition of mTORC1/2 Overcomes Resistance to MAPK Pathway Inhibitors Mediated by PGC1 α and Oxidative Phosphorylation in Melanoma. <i>Cancer Research</i> , 2014, 74, 7037-7047.	0.4	161
80	The Immune Microenvironment Confers Resistance to MAPK Pathway Inhibitors through Macrophage-Derived TNF α . <i>Cancer Discovery</i> , 2014, 4, 1214-1229.	7.7	174
81	Clinical Profiling of BCL-2 Family Members in the Setting of BRAF Inhibition Offers a Rationale for Targeting De Novo Resistance Using BH3 Mimetics. <i>PLoS ONE</i> , 2014, 9, e101286.	1.1	42
82	A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors. <i>Cancer Discovery</i> , 2014, 4, 816-827.	7.7	448
83	BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2013, 19, 1225-1231.	3.2	832
84	Whole exome and whole transcriptome sequencing in melanoma patients to identify mechanisms of resistance to combined RAF/MEK inhibition.. <i>Journal of Clinical Oncology</i> , 2013, 31, 9015-9015.	0.8	3